A new radiopharmaceutical compound (131I-PR81) for radioimmunotherapy of breast cancer: Labeling of antibody and its quality control

Human Antibodies

Volumn 19, Issue 4, 2010, Pages 79-88

  Mohammadnejad, J ^a   Rasaee, M J ^a   Babaei, M H ^b   Paknejad, M ^c   Zahir, M H ^a   Salouti, M ^d   Rajabi, A Bitarafan ^e   Mazidi, M ^b  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b ATOMIC ENERGY ORGANIZATION OF IRAN   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d ISLAMIC AZAD UNIVERSITY   (Iran)

^e IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

monoclonal antibody PR81; MUC1; radioimmunotherapy; Radioiodination

Indexed keywords

IODINE 131; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY PR81 I 131; MUCIN 1; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY LABELING; ARTICLE; BREAST CANCER; CELL STRAIN MCF 7; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; FEMALE; IMMUNOSCINTIGRAPHY; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUALITY CONTROL; RADIOIMMUNOTHERAPY; TISSUE DISTRIBUTION; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; IODINE RADIOISOTOPES; ISOTOPE LABELING; MICE; MICE, INBRED BALB C; MUCIN-1; QUALITY CONTROL; RADIOIMMUNODETECTION; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION;

EID: 78650608031     PISSN: 10932607     EISSN: None     Source Type: Journal    
DOI: 10.3233/HAB-2010-0231     Document Type: Article

References (21)

1. D.M. Goldenberg, Advancing role of radiolabeled antibodies in the therapy of cancer, Cancer Immunology Immunotherapy 52 (2003), 281.
2. 131I for use in radioimmunotherapy, The Journal of Nuclear Medicine 46 (2005), 153.
3. D.M. Goldenberg, Targeted therapy of cancer with radiolabeled antibodies, TheJournal of Nuclear Medicine 43 (2002), 693.
4. r. Molina, J. Jo, X. Fillela, G. Zanon, J. Pashia, M. Munoz, B. Farrus, M.L. Latre, J. Escriche and A.M. Ballesta, C-erbB-2 oncoprotein, CEA, and CA153 in patients with breast cancer: prognosis value, Breast Cancer Research Treatment 51(2) (1999), 109.
5. M.R. Price, P.D. Rye, E. Petrakon, A.Murray, K. Brady and S. Imai, Summary report on the ISOBMTD-4workshop: Analysis of 56monoclonal antibodies against theMUC1 mucin. San Diego. 17-23 Nov 1996, Tumor Biology 19(supp11) (1998), 1.
6. 90 - linked monoclonal MUC1 antibodies, Critical Reviews in Oncology-Hematology 38 (2001), 25.
7. A. Geoffrey, W. Li, K. Kenia, B. Terry, W. Daniel and I.F.C. McKenzie, Comparison of the biological properties of two anti-mucin-1 antibodies prepared for imaging and therapy, Cancer Immunology Immunotherapy 44 (1997), 323.
8. G. Kohler and C. Milstein, Continuous cultures of cells secreting antibody of predefined specificity, Nature 256 (1975), 495-497.
9. M. Paknejad, M.J. Rassae, F. Karami, S. Kashanian, M.A. Mohagheghi, K. Omidifar and M. Rajabibazel, Production of monoclonal antibodes PR81, recognizing the tandem repeat region ofMUC1, Hybridoma & Hybridomics 23 (2003), 153-158.
10. M. Mohammadi, M.J. Rasaee, M. Rajabibazl, M. Paknejad, M. Zare and S. Mohammadzadeh, Epitope mapping of PR81 anti-MUC1 monoclonal antibody following PEPSCAN and phage display techniques, Hybridoma (Larchmt) 26(4) (2007), 223-230.
11. N. Golmakany, M.J. Rasaee, M. Forouzandeh, A. Shojaosadati, S. Kashanian and K. Omidfar, Continuous production of monoclonal antibody in a packed-bed bioreactor, Biotechnol Appl Biochem 41(3) (2005), 272.
12. J. Mohammadnejad, M.J. Rasaee, B. Saqhafi, M. Rajabibazl, F. Rahbarizadeh and K. Omidfar, A New Competitive Enzyme Linked Immunosorbent Assay (MRP83-CA15-3) for MUC1 measurement in Breast Cancer, Journal of Immunoassay & Immunochemistry 27 (2006), 139.
13. S. Matzku, G. moldenhauer, H. Kalthoff, S. Canevari, M. Colanaghi, J. Schuhmacher and H. Bihl, Antibody transport and internalization into tumors, British Journal of Cancer 62 (1990), 1.
14. M. Brayman, A. Tathian and D. Carson, MUC1: A multi functional cell surface component of reproductive tissue epithelia, Reprod Biol Endocrinol 2(1) (2004), 4.
15. K.L. Cheung, C.R.L. Graves and J.F. Robertson, Tumormarker measurement in the diagnosis and monitoring of breast cancer, Cancer Treat Rev 26 (2000), 91.
16. G.A. Pietersz and I.F.C. McKenzie, Antibody conjugates for the treatment of cancer, Immunol Rev 129 (1992), 57.
17. H.J. Lee and W. Pardridge, Monoclonal antibody radiopharmaceuticals: cationization, pegylation, radiometal chelation, pharmacokinetics, and tumor imaging, Bioconjugate Chem 14 (2003), 546.
18. 131I-anti-CD45 antibody in congenic and H2mismatched murine transplant models, Blood 93 (1999), 737.
19. F.F. Catherine, J.R. Craig, D.B. Darell and R.Z. Michael, Radioiodination via D amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody, Cancer Research 60 (2000), 4453.
20. B.W. Jame, J.S. Christoper, R.P. Nigle and R.S. Michael, Radioimmunotherapy of breast cancer xenografts with monoclonal antibody ICR12 against cerbB2 p185: Comparison of iodogen and Nsuccinimidyl 4methyl3( trinbutylstannyl) benzoate radioiodination methods, Cancer Research 55 (1995), 5842.
21. O.W. Press, J. Howell-Clark, S. Anderson and I. Bernstein, Retention of Bcell specific monoclonal antibodies by human lymphoma cells, Blood 83 (1994), 139.